one skilled in the art will understand that the embodiment of the present invention as shown in the drawings and described above is exemplary only and not intended to be limited . an adenovirus vector used in the present invention is the product from stratagene company , and not intended to be limited . referring to fig1 and 2 , a construction of a r72 type tumor suppressor p53 according to a first preferred embodiment of the present invention is illustrated , wherein the construction adapts a cloning human p53 gene as a template , as shown in fig1 , and a gene mutation technology to mutate a proline codon ccc ( p72 ) to a arginine codon cgg ( r72 ) of a codon 72 of a human wild - type p53 gene , so as to form a new nucleotide endonuclease small site in the mutant region . in order to avoid the mutation of the other coding sequence of the wild - type p53 during the mutant procedure , the present invention adapts a sub reaction of pcr , so that a reactant from the pcr sub reaction will be combined to complete the r72 type tumor suppressor p53 construction after determining the sequence of the reactant from the pcr reaction is correct . ( 1 ). amplification of a fragment from nco1 site of 5 ′- terminal to codon 72 of human wild - type tumor suppressor p53 gene : human wild - type tumor suppressor p53 gene is used as the template to amplify the fragment desired by synthetic primers for pcr . the pcr product is added an adenine by a tailing process , then ligated to plasmid t - easy vector , and then the plasmid is transformed into bacteria for amplification , and the plasmid dna is extracted from bacteria and purified , and is finally determined by enzyme digest and dna sequencing . ( 2 ). amplification of a fragment from the 72 codon to nco1 site of c - terminal of human wild - type tumor suppressor p53 gene : human wild - type tumor suppressor p53 gene is used as the template again to amplify the fragment desired by synthetic primers for pcr . combining the amplified two production of pcr to the t - easy vector as the same method as the step 1 ), and determining the two products of pcr by the dna sequencing . ( 3 ). combining the above two products of pcr of the step ( 2 ) to form a nco1 ˜ nco1 fragment : digesting the t - easy vector plasmid dna of the above dna fragment of steps ( 1 ) and ( 2 ), then purifying to combine with the wild - type p53 gene cdna which is digested by the nco1 enzyme , and then transforming it into bacteria , extracting the plasmid , and determining the correct recombinant vector by the enzyme digestion to construct the r72 type p53 gene expression plasmid pcmv - neo - p53 , as shown in fig2 . referring to fig3 , cloning of p53aip1 according to a second preferred embodiment of the present invention is illustrated : 1 ). after 48 hours , collecting the apoptosis cells of hela tumor cells transfected with expression plasmid of wild - type p53 gene , and then extracting the total nucleotide ribose to synthetic complementary deoxyribonucleic acid ( cdna ) through a method of reverse transcriptase . 2 ). applying the pcr technology to amplify p53aip1 gene : taking the above synthetic cdna as a template , and amplifying the pcr by a synthetic primer . the first primer : ( adding the endonuclease site sma1 at an end of n - terminal ) the second primer : ( adding the endonuclease site xba1 at an end of c - terminal ) the pcr amplification production is added an adenine by a tailing process , then ligated to a t - easy vector and transformed into bacteria , and then amplified , extracted , purified , and determined the t - easy plasmid having pcr product ( p53aip1 ) by method of dna sequencing . 3 ). ligating the sequencing proved p53aip1 gene fragment to eukaryotic cell expression plasmid pcmv - neo vector in a correct direction , so as to construct a pcmv - neo - p53aip1 expression plasmid . an observation of the tumor suppressor p53 , r72 type tumor suppressor p53 and p53aip1 , and a synergy of both of the r72 type tumor suppressor p53 and p53aip1 to the tumor cell apoptosis according to a third embodiment of the present invention . the present invention applies the above gene and the gene combination to carry out the research of anti - tumor effects of variable tumor cell lines , including lung cancer h460 , cervical cancer hela , brain glioma , breast cancer , and prostate cancer , in vitro , wherein the research shows that r72 type tumor suppressor p53 and p53aip1 co - transfection tumor cell has the strongest anti - cancer function . take the lung cancer h460 for example to describe the third embodiment as below . first , according to the design of this experiment , take a 10 % calf serum dmem medium and under a carbon dioxide incubator with 5 % carbon dioxide and 37 ° c . temperature to culture the lung cancer cells h460 until a petri dish is 80 % covered by the lung cancer cells . remove the medium and add the new made medium into the petri dish to culture the cell for another three hours . add 100 micro - liter , 1 . 5m salt solution into a sample of plasmid dna 4 microgram of wild - type p53 , r72 type p53 , p53aip1 , wild - type p53 + p53aip1 , and mutant type p53 + p53aip1 respectively and well mix each of the samples above , according to the description of the jetpei ™ transfection reagent product . at the same time , add 6 micro - liter jetpei ™ transfection reagent into 100 micro - liter 1 . 5m salt solution and well mix it . slowly add the well mixed jetpei ™ transfection reagent into the plasmid dna salt solution and well mix it . resting place at the room temperature for 30 minutes , and then drip the transfection reagent containing the plasmid dna into the cell medium . take the jetpei ™ transfection reagent as a control group . after culturing for 48 hours , centrifuge to collect the floating lung cancer cells , and count the number of apoptosis cells of the different groups to statistically analyze it . repeat this experiment for three times to get an average data . the result shows that the ability of the apoptosis of the r72 type p53 is stronger than the wild - type p53 , and the r72 type tumor suppressor p53 and p53aip1 co - transfection of tumor cell have the strongest anti - cancer effect , as shown in fig4 . referring to fig4 , a synthetic and cloning of the tumor - specific promoter dna fragment according to a fourth embodiment of the present is illustrated . according to a known gene sequence , the tumor - specific promoter dna fragment is synthesized , and pcr amplified by the following primers : the first primer : ( adding the endonuclease site nru1 , kpn1 , and xba1 at the end of n - terminal ) the pcr amplification production is added an adenine by a tailing process , then ligated to plasmid t - easy vector and transformed into bacteria , and then amplified , extracted , purified , and determine the pcr product for tumor specific promoter ligated to the plasmid t - easy by dna sequencing method . referring to fig5 and 6 of the drawings , a construction of an expression cassette comprises the tumor - specific promoter , variety of p53 , internal ribosome entry site ( ires ), and p53aip1 according to a fifth embodiment of the present invention is illustrated . in the fifth embodiment of the present invention , the plasmid pires - neo is adapted as a vector for the construction of expression cassette . through a serious of endonuclease digestion , ligation reaction , transformation of competent bacterial and dna sequencing , it was confirmed that the construction of the expression cassette was completed . the process includes : 1 . take the fragment between sma1 site of 5 ′- terminat and xba1 site of 3 ′- terminal of the p53aip1 gene to link to ires and sv40 polyadenylation signal and located at the downstream of ires ; 2 . take the fragment of not1 site of 5 ′- terminal and ecor1 site of 3 ′- terminal of variety of p53 to insert between tumor - specific promoter and ires , and locate at the downstream of the promoter ; 3 . take the fragment between kpn1 site of 5 ′- terminal and not1 site of 3 ′- terminal of the peg - 3 promoter to insert between the vector with cmv promoter deleted and the variety of p53 . until now the construction of expression cassette of the pires plasmid ( ppeg - 3prom .- p53 - ires - p53aip1 ) is completed . referring to fig7 , a construction of an adenovirus shuttle plasmid containing the expression cassette according to a sixth embodiment of the present invention is illustrated . 1 ). digest the pires plasmid dna described as above by enzyme kpn1 and sal1 to produce two dna fragments of kpn1 - kpn1 and kpn1 - sal1 , which includes the sv40 poly - adenine dna sequence , and then the digested dna is separated by 1 . 2 % agarose gel electrophoresis and purified for the later use . 2 ). digest adenovirus pshuttle plasmid dna by enzyme kpn1 and sal1 , and then digested reactant is separated by 1 . 2 % agarose gel electrophoresis and purified for the later use . 3 ). under the effect of ligase enzyme , the above linearization pshuttle plasmid dna is ligated to kpn1 - kpn1 and kpn1 - sal1 fragments produced from digestion of the expression cassette , and the ligated reactant was transformed into competent bacteria . 4 ). screening of the bacteria strains , cultivate the transformants , and then extract the recombinant plasmid dna , and finally to prove it by enzyme digestion and dna sequencing . a preparation of a recombinant adenovirus of target - oriented co - expressing variety of p53 and p53aip1 gene according to a seventh embodiment of the present invention is illustrated : 1 ). the preparation of linearization recombinant plasmid dna of pshuttle - p53 - p53aip1 containing expression cassette comprising variety of p53 and p53aip1 gene : take appropriate amount of the above recombinant shuttle plasmid dna to be digested by a endonuclease pme1 , separated by the electrophoresis , and purified the linearization recombinant shuttle plasmid dna for the later use . 2 ). the above linearization recombinant shuttle plasmid dna is electroporated into bj5183 - ad - 1 bacteria pre - transformed with adenovirus vector padeasy - 1 for homologous recombination , and the bacteria are screened on the lb - broth containing kanamycin antibiotics , wherein the strains resistance to kanamycin are the bacteria having the recombinant adenovirus padeasy - 1 - p53 - p53aip1 . 3 ). cultivate the bacteria strain resistance to kanamycin to amplify , and extract recombination adenovirus padeasy - 1 - p53 - p53aip1 dna from the bacteria , and then linearize the recombination adenovirus padeasy - 1 - p53 - p53aip1 plasmid dna by digestion with enzyme pac1 , and purify it for later use . 4 ). the linearized recombination adenovirus padeasy - 1 - p53 - p53aip1 plasmid dna is used to transfect embryonic kidney ad - 293 cell to allow the recombination adenovirus padeasy - 1 - p53 - p53aip1 to be packaged to make it become infectious viral particles . 5 ). preparation of primary recombinant adenovirus stock with recombinant adenovirus padeasy - 1 - p53 - p53aip1 by removing growth medium from adenovirus - producing ad - 293 cell plate after the transfection of embryonic kidney ad - 293 cell for 7 - 10 days , and obtaining adequate amount of the high - titration recombinant adenovirus by infection of the embryonic kidney ad - 293 cells with a low passage viral stock . it will thus be seen that the objects of the present invention have been fully and effectively accomplished . the embodiments have been shown and described for the purposes of illustrating the functional and structural principles of the present invention and is subject to change without departure from such principles . therefore , this invention includes all modifications encompassed within the spirit and scope of the following claims .